Abstract
The scenario of systemic therapy for prostate cancer is rapidly evolving, with new drugs and new treatment options. To update the background knowledge of shared uro-oncologic practice, we reviewed current statements and landmarks in systemic therapy. A number of new agents are under investigation in non-metastatic and metastatic disease. Similarly, new target imaging technologies are under development to improve the detection rate of true non-metastatic and true metastatic patient. Five new drugs have shown to be effective on progression-free and overall survival in metastatìc prostate cancer. However, the optimal sequencing of these treatments requires further investigation. The tolerability and side effects of the new drugs are also crucial issues to be discussed, as well as their activity against the disease. The uro-oncologic team has to stay updated about new medical therapies in order to be confident in debating with other professionals involved in prostate cancer decision making. Different points of view and nuances should be shared during multidisciplinary group discussions to achieve a balanced decision in disease management.
Keywords: Prostate cancer, androgen deprivation therapy, antiandrogens, prostate cancer unit, docetaxel, systemic therapy.
Current Cancer Drug Targets
Title:Management of Prostate Cancer with Systemic Therapy: A Prostate Cancer Unit Perspective
Volume: 21 Issue: 2
Author(s): Fabio Campodonico*, Marco Ennas, Silvia Zanardi , Ekaterini Zigoura, Arnoldo Piccardo, Luca Foppiani, Concetta Schiavone, Lino Squillace, Andrea Benelli, Andrea De Censi , Filippo Grillo-Ruggieri and Carlo Introini
Affiliation:
- Department of Abdominal Surgery, Urology, Galliera Hospital, Genova,Italy
Keywords: Prostate cancer, androgen deprivation therapy, antiandrogens, prostate cancer unit, docetaxel, systemic therapy.
Abstract: The scenario of systemic therapy for prostate cancer is rapidly evolving, with new drugs and new treatment options. To update the background knowledge of shared uro-oncologic practice, we reviewed current statements and landmarks in systemic therapy. A number of new agents are under investigation in non-metastatic and metastatic disease. Similarly, new target imaging technologies are under development to improve the detection rate of true non-metastatic and true metastatic patient. Five new drugs have shown to be effective on progression-free and overall survival in metastatìc prostate cancer. However, the optimal sequencing of these treatments requires further investigation. The tolerability and side effects of the new drugs are also crucial issues to be discussed, as well as their activity against the disease. The uro-oncologic team has to stay updated about new medical therapies in order to be confident in debating with other professionals involved in prostate cancer decision making. Different points of view and nuances should be shared during multidisciplinary group discussions to achieve a balanced decision in disease management.
Export Options
About this article
Cite this article as:
Campodonico Fabio *, Ennas Marco, Zanardi Silvia , Zigoura Ekaterini , Piccardo Arnoldo , Foppiani Luca , Schiavone Concetta , Squillace Lino , Benelli Andrea , De Censi Andrea , Grillo-Ruggieri Filippo and Introini Carlo , Management of Prostate Cancer with Systemic Therapy: A Prostate Cancer Unit Perspective, Current Cancer Drug Targets 2021; 21 (2) . https://dx.doi.org/10.2174/1568009620666201021163919
DOI https://dx.doi.org/10.2174/1568009620666201021163919 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Eriocalyxin B-Induced Apoptosis in Pancreatic Adenocarcinoma Cells Through Thiol-Containing Antioxidant Systems and Downstream Signalling Pathways
Current Molecular Medicine Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment
Current Drug Targets Small Molecule Kinase Inhibitors as Anti-Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry Novel Patented Src Kinase Inhibitor
Current Medicinal Chemistry CRM1-Mediated Nuclear Export of Proteins and Drug Resistance in Cancer
Current Medicinal Chemistry Molecular Mechanisms of Pancreatic Cancer Dissemination: The Role of the Chemokine System
Current Pharmaceutical Design Distinctive Cellular Roles for Novel Protein Kinase C Isoenzymes
Current Pharmaceutical Design HR MAS MR Spectroscopy in Metabolic Characterization of Cancer
Current Topics in Medicinal Chemistry Perspective of MiRNAs in Clinical Glioblastoma Research
Current Signal Transduction Therapy Integrin α3 Mediates Stemness and Invasion of Glioblastoma by Regulating POU3F2
Current Protein & Peptide Science Nitric Oxide in Cancer Therapeutics: Interaction with Cytotoxic Chemotherapy
Current Pharmaceutical Design Methylenetetrahydrofolate Reductase (MTHFR): A Novel Target for Cancer Therapy
Current Pharmaceutical Design Novel 3-substituted-2-oxoindoline-based N-hydroxypropenamides as Histone Deacetylase Inhibitors and Antitumor Agents
Medicinal Chemistry Anticancer Antifolates: Current Status and Future Directions
Current Pharmaceutical Design Synthesis and Biological Evaluation of 2´-Hydroxy-4´,6´-Diprenyloxychal-Cone Derivatives as Potent CDC25B and PTP1B Inhibitors
Letters in Drug Design & Discovery Role of Flavonoids in the Prevention of Gynecological Cancers: Epidemiological Clues
Current Women`s Health Reviews Hepatocyte Growth Factor Signaling in Cancer Metastasis
Current Signal Transduction Therapy Genomic Organization and Control of the Grb7 Gene Family
Current Genomics A Novel Approach for Aerobic Construction of Iron Oxide Nanoparticles by Acinetobacter radioresistens and their Effects on Red Blood Cells
Current Nanoscience Editorial: Big Data and New Drug Discovery: Tackling “Big Data” for Virtual Screening of Large Compound Databases
Current Computer-Aided Drug Design